Rare disease advocates perplexed by mixed messages at the FDA

Two years ago, Megan Selser was in the midst of folding her 7-week-old infant’s clothes, embracing his fuzzy red head against her chest, when her phone suddenly rang. The voice on the other end delivered news that would forever change her life – her son Ben had been diagnosed with mucopolysaccharidosis (MPS) type 2, also known as Hunter Syndrome. This rare disease, though invisible at birth, slowly deteriorates a child’s physical and cognitive abilities, with some children tragically passing away as young as 10.

Despite the devastating diagnosis, there was a glimmer of hope for Ben. Thanks to a newborn screening pilot project in North Carolina, his condition was caught early. Doctors informed Megan that there were new treatments in clinical trials, including two gene therapies and a protein-based drug, that had the potential to alter the disease’s progression if administered promptly.

However, this month, those hopes were dealt a significant blow when the Food and Drug Administration (FDA) rejected a gene therapy from Regenxbio. The regulatory agency cited the need for more data collection, potentially delaying approval by several years. This rejection marks just one of at least five cell or gene therapies for rare, life-threatening diseases that the FDA has recently rejected or appeared to backtrack on since new leadership took office under the Trump administration.

The rejection of Regenxbio’s MPS drug has sparked concern among advocates and industry executives that the FDA may be retracting from the flexible regulatory approach that had been promised in recent years. The decision has left families like Megan Selser’s in a state of uncertainty, as they navigate the complexities of rare disease treatment and the regulatory landscape.

As the search for effective treatments for rare diseases continues, the rejection of promising therapies like Regenxbio’s gene therapy serves as a stark reminder of the challenges faced by patients and families in accessing potentially life-changing treatments. The hope now lies in continued research, collaboration, and advocacy to ensure that innovative therapies can reach those who need them most.